menu
    • menu

    Company profile for Contineum Therapeutics

    NEW Drugs in Dev: 3
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Contineum Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology (NI&I) indications with significant unmet medical needs. Our focus is on targeting biological pathways associated with specific clinical disabilities, aiming to modulate them in ways that can positively impact the course of disease. The c...
    Contineum Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology (NI&I) indications with significant unmet medical needs. Our focus is on targeting biological pathways associated with specific clinical disabilities, aiming to modulate them in ways that can positively impact the course of disease. The company boasts a robust pipeline of internally developed programs aimed at addressing various NI&I disorders.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Contineum TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    San Diego, CA 92121
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.contineum-tx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/contineumtherapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PCHi

    PCHi

    Not Confirmed

    envelop Contact Supplier

    PCHi

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Continuum Therapeutics to Present at 2026 Leerink Conference
    Continuum Therapeutics to Present at 2026 Leerink Conference

    03 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260303064253/en/Contineum-Therapeutics-to-Present-at-the-2026-Leerink-Partners-Global-Healthcare-Conference

    BUSINESSWIRE
    03 Mar 2026
    Share Share
    Contineum Therapeutics Discloses Inducement Grant Per Nasdaq LR
    Contineum Therapeutics Discloses Inducement Grant Per Nasdaq LR

    18 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260218230467/en/Contineum-Therapeutics-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635c4

    BUSINESSWIRE
    18 Feb 2026
    Share Share
    Continuum Therapeutics Inducement Under Nasdaq Rule 5635(c)(4)
    Continuum Therapeutics Inducement Under Nasdaq Rule 5635(c)(4)

    28 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260128919609/en/Contineum-Therapeutics-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635c4

    BUSINESSWIRE
    28 Jan 2026
    Share Share
    Contineum Therapeutics Plans $75M Public Offering
    Contineum Therapeutics Plans $75M Public Offering

    11 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251211081244/en/Contineum-Therapeutics-Announces-Proposed-%2475.0-Million-Public-Offering

    BUSINESSWIRE
    11 Dec 2025
    Share Share
    Continuum Therapeutics at 8th Evercore ISI Healthcare Conf
    Continuum Therapeutics at 8th Evercore ISI Healthcare Conf

    24 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251124649214/en/Contineum-Therapeutics-to-Attend-the-8th-Annual-Evercore-Healthcare-Conference

    BUSINESSWIRE
    24 Nov 2025
    Share Share
    J&J, Contineum Fail 'Risky' Mid-Stage Multiple Sclerosis Trial
    J&J, Contineum Fail 'Risky' Mid-Stage Multiple Sclerosis Trial

    21 Nov 2025

    // BIOSPACE

    https://www.biospace.com/drug-development/j-j-contineum-fail-risky-mid-stage-multiple-sclerosis-trial

    BIOSPACE
    21 Nov 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search